Use of Hydrochlorothiazide in Patients with Impaired Renal Function

Introduction to Hydrochlorothiazide Use

The European Society of Cardiology recommends that Hydrochlorothiazide (HCTZ) should be avoided or replaced with loop diuretics in patients with severe renal impairment, as it becomes ineffective when creatinine clearance falls below 30 mL/min 1, 2

Thiazide diuretics, such as HCTZ, lose their effectiveness when creatinine clearance falls below 30 mL/min, making loop diuretics the preferred choice in severe renal impairment, according to the European Heart Journal 1, 2

For patients with normal renal function (GFR >90 mL/min), the standard dosing of HCTZ is recommended, as suggested by the British Journal of Pharmacology 3, 4
In patients with severe renal impairment (GFR <30 mL/min), HCTZ is ineffective and should be avoided, and loop diuretics should be considered instead, as recommended by the European Heart Journal 1, 2

The European Heart Journal recommends monitoring renal function and electrolytes closely when initiating or adjusting HCTZ in patients with any degree of renal impairment, with particular attention to serum potassium, magnesium, blood pressure, signs of dehydration, and worsening renal function 3, 5
There is an increased risk of electrolyte disturbances, including hyponatremia, hypomagnesemia, hyperglycemia, and hyperuricemia, in patients with renal impairment taking HCTZ, as reported by the European Heart Journal 5
The European Heart Journal also notes a risk of pre-renal azotemia and further deterioration of renal function in patients with renal impairment taking HCTZ 5

Patients with heart failure and renal dysfunction often require more intensive diuretic therapy due to excessive salt and water retention, as noted by the European Heart Journal 2
Elderly patients are at higher risk of adverse effects due to age-related decline in renal function and should be monitored more closely, according to the European Heart Journal 6
The American Heart Association is not mentioned in this article, however, the European Heart Journal recommends considering the interaction with other medications that may worsen renal function or electrolyte abnormalities (e.g., NSAIDs, ACE inhibitors, ARBs) 7

In patients with severe renal impairment (GFR <30 mL/min), the British Journal of Pharmacology suggests that HCTZ should be avoided completely and loop diuretics should be considered instead 8

The European Society of Cardiology recommends checking renal function and electrolytes at baseline before initiating HCTZ, and follow-up monitoring should be performed 1-2 weeks after initiation or dose change of HCTZ 9
The European Society of Cardiology recommends discontinuation of diuretics in the event of worsening renal impairment or dehydration 10
Renal function and electrolytes should be monitored at baseline and 1-2 weeks after initiation of HCTZ 10, 9

Assess baseline renal function (GFR/creatinine clearance) before initiating HCTZ, as recommended by the European Journal of Heart Failure 9
If significant worsening of renal function occurs, the British Journal of Pharmacology suggests discontinuing HCTZ 10

The American Journal of Kidney Diseases recommends avoiding the combination of HCTZ with NSAIDs, as this significantly increases nephrotoxicity risk, and exercising caution when patients are on ACE inhibitors or ARBs, as the combination increases risk of acute kidney injury and electrolyte abnormalities 11
The American Journal of Kidney Diseases suggests temporarily suspending RAAS antagonists during intercurrent illness or before procedures to minimize the risk of adverse effects 11
The American Journal of Kidney Diseases advises against continuing HCTZ in patients whose renal function deteriorates to GFR <30 mL/min during treatment, and against assuming dose adjustment will make HCTZ effective in severe renal impairment 11
The American Journal of Kidney Diseases recommends discontinuing HCTZ during acute illness, as intercurrent illness, dehydration, or procedures requiring contrast can precipitate acute kidney injury 11
The American Journal of Kidney Diseases warns against overlooking drug interactions, as NSAIDs and RAAS inhibitors substantially increase risk 11